




INFLUENZA

Treatment



Statistics

Swine flu (2009)




250'000 deaths.


Europe & US (2019)



2'400'000 hospitalisations



OBJECTIVE



Resistant host

Tolerant host

Susceptible host



DRUGSILIENCE

The strong choice

Virtual screening



A. Ducrot



W. Verstraeten

In Vitro studies



B. Berneron



A. Grisard

In Vivo & IND Enabling studies



L. Cabizzosu



M. Lazzaroni




S. Bonnin

Clinical Trials



B. Delecourt




C. Calisti




S. Leonova

ETC/UPRmt

ETC/UPRmt Pathway








Virtual screening



Mitoribosome




Docking Site: mS27




De novo drug template


9TB




ATC



COL-3



In Vitro assays



In vivo Optimisation & IND Enabling Studies

- Oral administration 
- Intravenous (IV) administration 

Steps

MitoCycline

In vivo assays

Toxicology Assays
PK/PD evaluation
General toxicology
Carcinogenicity
Genotoxicity
Immunotoxicity

Efficacy
PK/PD evaluation
UPRmt activation
BAL fluid analysis


Embryo-Fetal Toxicity
Fetal death
Fetal malformations
Fetal teratomas

IND Enabling Studies
PK/PD evaluation
Pharmaco-Toxicity
Dose refinement
GMP manufacturing

Animal models



Clinical Trials





Why MitoCycline ?



Antivirals treatments



Fast hospital turnover



Fast development

- Short clinical trials



Large market

- COVID-19,
Hepatitis C



General mode of action


- Generic treatment for
different pathogens

Exit Strategy




FINANCIAL


Business strategy




Financial Exit Strategy



Business strategy



Time to benefits





1 billion people
500 000 deaths



Tolerant host

Induce tolerance by activating ETC/
UPRmt

Work Flow:



Mitocycline:



mS 27 of the mitoribosome



Development cost 109M\$



Revenue over
100M\$ by year 1

